General Dynamics to develop new DOD WMD modeling software

General Dynamics' IT business unit has won a potential five-year, $45 million contract to build software for the U.S. military to model effects of incidents involving weapons of mass destruction or toxic materials.

The Army awarded the single-award-indefinite delivery, indefinite-quantity contract for the Joint Effects Model Increment 2 software. Northrop Grumman was the contractor for JEM Increment 1.

JEM is a web-based software application that works to simulate and measure effects of strikes or release incidents of chemical, biological, radiological and nuclear weapons or toxic industrial materials. The Defense Department uses JEM to model and predict time-phased impacts of events based on weather and terrain, among other areas.

General Dynamics will act as integrator, field system updates and perform systems engineering work for Increment 2.

About the Author

Ross Wilkers is a senior staff writer for Washington Technology. He can be reached at Follow him on Twitter: @rosswilkers. Also find and connect with him on LinkedIn.

Reader Comments

Please post your comments here. Comments are moderated, so they may not appear immediately after submitting. We will not post comments that we consider abusive or off-topic.

Please type the letters/numbers you see above

What is your e-mail address?

My e-mail address is:

Do you have a password?

Forgot your password? Click here


  • POWER TRAINING: How to engage your customers

    Don't miss our Aug. 2 Washington Technology Power Training session on Mastering Stakeholder Engagement, where you'll learned the critical skills you need to more fully connect with your customers and win more business. Read More


    In our latest Project 38 Podcast, editor Nick Wakeman interviews Tom Romeo, the leader of Maximus Federal about how it has zoomed up the 2019 Top 100. Read More

contracts DB

Washington Technology Daily

Sign up for our newsletter.

Terms and Privacy Policy consent

I agree to this site's Privacy Policy.